Slow‐, Tight‐Binding HIV‐1 Reverse Transcriptase Non‐Nucleoside Inhibitors Highly Active against Drug‐Resistant Mutants
- 4 April 2007
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 2 (4) , 445-448
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Current Developments in HIV ChemotherapyChemMedChem, 2006
- Computer-Aided Design, Synthesis, and Anti-HIV-1 Activity in Vitro of 2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)- ones as Novel Potent Non-Nucleoside Reverse Transcriptase Inhibitors, Also Active Against the Y181C VariantJournal of Medicinal Chemistry, 2004
- Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and FutureChemistry & Biodiversity, 2004
- Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): The DABOs familyDrugs of the Future, 2002
- 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine DerivativesJournal of Medicinal Chemistry, 1999
- The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1Antiviral Research, 1998
- Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO SeriesJournal of Medicinal Chemistry, 1997
- Preparation and anti-HIV-1 activity of Thio Analogues of DichydroalkoxybenzyloxopyrimidinesJournal of Medicinal Chemistry, 1995
- Synthesis and Antiviral Activity of New 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs), Specific Inhibitors of Human Immunodeficiency Virus Type 1Antiviral Chemistry and Chemotherapy, 1995
- 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1Antiviral Chemistry and Chemotherapy, 1993